Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults With Schizophrenia, Schizophreniform, or Bipolar I Disorder Who Are Early in Their Illness

NCT03187769 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT03187769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03187769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults With Schizophrenia, Schizophreniform, or Bipolar I Disorder Who Are Early in Their Illness
Lead sponsor
Alkermes, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 8, 2017
Completion date
January 3, 2022
Enrollment
426 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar i disorder, schizophrenia, schizophreniform disorders